Compare Alcon AG (ALC) vs iShares Bitcoin Trust (IBIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs iShares Bitcoin Trust — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while iShares Bitcoin Trust trades at $35.28. The key difference: Alcon AG pays a 0.54% dividend while iShares Bitcoin Trust pays none, and Alcon AG is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| ALC | IBIT | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Crypto-linked |
52-Week High | $92.22 | $71.29 |
52-Week Low | $62.02 | $33.29 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
IBIT trades at $36.12, up 3.58% today, with a bullish technical signal despite bearish moving averages. Key support lies at $35 and resistance at $37. The stock faces headwinds from sector volatility and significant ETF outflows, as reported by Zacks Investment Research on 2026-07-06. Recent news highlights competitive pressures among Bitcoin ETFs, with IBIT leading in assets under management according to The Motley Fool on 2026-06-29.
The outlook remains cautious due to market sentiment shifts and regulatory uncertainties. Investment opportunities hinge on the company's ability to maintain its asset scale advantage, while risks include continued investor outflows and broader crypto market declines impacting related equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →
